Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer. To facilitate the further integration of our science, technology and data and build on the strong alignment of our commercial, medical and policy teams, the responsibilities of this role will be redistributed to James E. Bradner, Executive Vice President, Research and Development, Artificial Intelligence and Data, Murdo Gordon, Executive Vice President, Amgen Global Markets and Policy, and Peter H. Griffith, Executive Vice President and Chief Financial Officer, each effective as of June 1, 2026. Dr. Reese will remain employed as an Executive Vice President until his retirement on June 30, 2026. Departure of Executive Vice President On June 30, 2026, Dr. Reese will retire from the role of Executive Vice President. At that time, Dr. Reese will be retirement eligible under the Company’s plans and policies and, upon his departure from the Company on June 30, 2026, he will receive the retirement benefits set forth in the Company’s plans and described in the Company’s filings, including the Company’s 2026 Proxy Statement. Additional Information A copy of the press release announcing Dr. Reese’s retirement from the role of the Company’s Executive Vice President and Chief Technology Officer is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 furnished herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filings of the Company under the Securities Act of 1933, as amended.
AMGN Amgen Inc - 8-K
Accession
0000318154-26-0000485.029.01
Item 5.02 - Departure/Election of Directors or Certain Officers
304 words
Item 9.01 - Financial Statements and Exhibits
29 words
Item 9.01 Financial Statements and Exhibits. Exhibit No. Document Description 99.1 Press Release dated April 22, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).